365 related articles for article (PubMed ID: 32143967)
1. Association Between RET Fusions and Efficacy of Pemetrexed-based Chemotherapy for Patients With Advanced NSCLC in China: A Multicenter Retrospective Study.
Shen T; Pu X; Wang L; Yu Z; Li J; Zhang Y; Liang X; Chen H; Xu C; Song Z; Wang W
Clin Lung Cancer; 2020 Sep; 21(5):e349-e354. PubMed ID: 32143967
[TBL] [Abstract][Full Text] [Related]
2. Unique Genetic Characteristics and Clinical Prognosis of Female Patients with Lung Cancer Harboring RET Fusion Gene.
Qiu Z; Ye B; Wang K; Zhou P; Zhao S; Li W; Tian P
Sci Rep; 2020 Jun; 10(1):10387. PubMed ID: 32587276
[TBL] [Abstract][Full Text] [Related]
3. Crizotinib vs platinum-based chemotherapy as first-line treatment for advanced non-small cell lung cancer with different ROS1 fusion variants.
Xu H; Zhang Q; Liang L; Li J; Liu Z; Li W; Yang L; Yang G; Xu F; Ying J; Zhang S; Wang Y
Cancer Med; 2020 May; 9(10):3328-3336. PubMed ID: 32168429
[TBL] [Abstract][Full Text] [Related]
4. Clinicopathologic characteristics, genetic variability and therapeutic options of RET rearrangements patients in lung adenocarcinoma.
Song Z; Yu X; Zhang Y
Lung Cancer; 2016 Nov; 101():16-21. PubMed ID: 27794403
[TBL] [Abstract][Full Text] [Related]
5. Clinical outcomes with pemetrexed-based systemic therapies in RET-rearranged lung cancers.
Drilon A; Bergagnini I; Delasos L; Sabari J; Woo KM; Plodkowski A; Wang L; Hellmann MD; Joubert P; Sima CS; Smith R; Somwar R; Rekhtman N; Ladanyi M; Riely GJ; Kris MG
Ann Oncol; 2016 Jul; 27(7):1286-91. PubMed ID: 27056998
[TBL] [Abstract][Full Text] [Related]
6. KIF5B-RET fusions in Chinese patients with non-small cell lung cancer.
Cai W; Su C; Li X; Fan L; Zheng L; Fei K; Zhou C
Cancer; 2013 Apr; 119(8):1486-94. PubMed ID: 23378251
[TBL] [Abstract][Full Text] [Related]
7. First-line crizotinib versus platinum-pemetrexed chemotherapy in patients with advanced ROS1-rearranged non-small-cell lung cancer.
Shen L; Qiang T; Li Z; Ding D; Yu Y; Lu S
Cancer Med; 2020 May; 9(10):3310-3318. PubMed ID: 32167664
[TBL] [Abstract][Full Text] [Related]
8. Clinical and prognostic implications of RET rearrangements in metastatic lung adenocarcinoma patients with malignant pleural effusion.
Tsai TH; Wu SG; Hsieh MS; Yu CJ; Yang JC; Shih JY
Lung Cancer; 2015 May; 88(2):208-14. PubMed ID: 25773866
[TBL] [Abstract][Full Text] [Related]
9. Characteristics and outcomes of RET-rearranged Korean non-small cell lung cancer patients in real-world practice.
Lee J; Ku BM; Shim JH; La Choi Y; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
Jpn J Clin Oncol; 2020 May; 50(5):594-601. PubMed ID: 32083304
[TBL] [Abstract][Full Text] [Related]
10. Characterization of Computed Tomography Imaging of Rearranged During Transfection-rearranged Lung Cancer.
Saiki M; Kitazono S; Yoshizawa T; Dotsu Y; Ariyasu R; Koyama J; Sonoda T; Uchibori K; Nishikawa S; Yanagitani N; Horiike A; Ohyanagi F; Oikado K; Ninomiya H; Takeuchi K; Ishikawa Y; Nishio M
Clin Lung Cancer; 2018 Sep; 19(5):435-440.e1. PubMed ID: 29885946
[TBL] [Abstract][Full Text] [Related]
11. Clinical and Translational Implications of RET Rearrangements in Non-Small Cell Lung Cancer.
Ferrara R; Auger N; Auclin E; Besse B
J Thorac Oncol; 2018 Jan; 13(1):27-45. PubMed ID: 29128428
[TBL] [Abstract][Full Text] [Related]
12. Characteristics and outcomes of patients with RET-fusion positive non-small lung cancer in real-world practice in the United States.
Hess LM; Han Y; Zhu YE; Bhandari NR; Sireci A
BMC Cancer; 2021 Jan; 21(1):28. PubMed ID: 33402119
[TBL] [Abstract][Full Text] [Related]
13. Comparison of the Efficacy between Pemetrexed plus Platinum and Non-Pemetrexed plus Platinum as First-Line Treatment in Patients with Wild-Type Epidermal Growth Factor Receptor Nonsquamous Non-Small Cell Lung Cancer: A Retrospective Analysis.
Kang EJ; Min KH; Hur GY; Lee SY; Shim JJ; Kang KH; Oh SC; Seo JH; Kim JS
Chemotherapy; 2016; 61(1):41-50. PubMed ID: 26517706
[TBL] [Abstract][Full Text] [Related]
14. Pemetrexed-Based Chemotherapy Is Inferior to Pemetrexed-Free Regimens in Thyroid Transcription Factor 1 (TTF-1)-Negative, EGFR/ALK-Negative Lung Adenocarcinoma: A Propensity Score Matched Pairs Analysis.
Frost N; Zhamurashvili T; von Laffert M; Klauschen F; Ruwwe-Glösenkamp C; Raspe M; Brunn M; Ochsenreither S; Temmesfeld-Wollbrück B; Suttorp N; Grohé C; Witzenrath M
Clin Lung Cancer; 2020 Nov; 21(6):e607-e621. PubMed ID: 32620471
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of platinum combination chemotherapy after first-line gefitinib treatment in non-small cell lung cancer patients harboring sensitive EGFR mutations.
Masuda T; Imai H; Kuwako T; Miura Y; Yoshino R; Kaira K; Shimizu K; Sunaga N; Tomizawa Y; Ishihara S; Mogi A; Hisada T; Minato K; Takise A; Saito R; Yamada M
Clin Transl Oncol; 2015 Sep; 17(9):702-9. PubMed ID: 25990507
[TBL] [Abstract][Full Text] [Related]
16. RET fusions as primary oncogenic drivers and secondary acquired resistance to EGFR tyrosine kinase inhibitors in patients with non-small-cell lung cancer.
Wang C; Zhang Z; Sun Y; Wang S; Wu M; Ou Q; Xu Y; Chen Z; Shao Y; Liu H; Hou P
J Transl Med; 2022 Sep; 20(1):390. PubMed ID: 36059009
[TBL] [Abstract][Full Text] [Related]
17. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry.
Gautschi O; Milia J; Filleron T; Wolf J; Carbone DP; Owen D; Camidge R; Narayanan V; Doebele RC; Besse B; Remon-Masip J; Janne PA; Awad MM; Peled N; Byoung CC; Karp DD; Van Den Heuvel M; Wakelee HA; Neal JW; Mok TSK; Yang JCH; Ou SI; Pall G; Froesch P; Zalcman G; Gandara DR; Riess JW; Velcheti V; Zeidler K; Diebold J; Früh M; Michels S; Monnet I; Popat S; Rosell R; Karachaliou N; Rothschild SI; Shih JY; Warth A; Muley T; Cabillic F; Mazières J; Drilon A
J Clin Oncol; 2017 May; 35(13):1403-1410. PubMed ID: 28447912
[TBL] [Abstract][Full Text] [Related]
18. A phase 2 study of lenvatinib in patients with RET fusion-positive lung adenocarcinoma.
Hida T; Velcheti V; Reckamp KL; Nokihara H; Sachdev P; Kubota T; Nakada T; Dutcus CE; Ren M; Tamura T
Lung Cancer; 2019 Dec; 138():124-130. PubMed ID: 31710864
[TBL] [Abstract][Full Text] [Related]
19. [Efficacy and safety of pemetrexed or gemcitabine combined with carboplatin as the first-line therapy in elderly patients with advanced non-small cell lung cancer].
Shi X; Yu XM; Zhang YP; Zhao J
Zhonghua Zhong Liu Za Zhi; 2013 Mar; 35(3):221-4. PubMed ID: 23880005
[TBL] [Abstract][Full Text] [Related]
20. RET-rearranged non-small-cell lung carcinoma: a clinicopathological and molecular analysis.
Tsuta K; Kohno T; Yoshida A; Shimada Y; Asamura H; Furuta K; Kushima R
Br J Cancer; 2014 Mar; 110(6):1571-8. PubMed ID: 24504365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
